{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the gene responsible for autosomal-dominant PD, PARK8... Accumulated data suggest that the kinase activity of LRRK2 may play a key role in neurodegeneration. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interaction with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegeneration caused by LRRK2 mutations.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neurodegeneration in Parkinson's disease linked to LRRK2 kinase activity, with reduced phosphorylation of Akt1 by mutant LRRK2 as a potential contributor to neuronal loss."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro phosphorylation of Akt1 by LRRK2... recombinant human Akt1 was incubated with recombinant human LRRK2... LRRK2 directly and effectively phosphorylated the heat-denatured Akt1 molecule. Knockdown of LRRK2 diminishes Akt1 phosphorylation in intact cells... transfection of LRRK2-specific RNAi into the cells reduced the level of LRRK2 protein... resulted in a marked reduction of phospho-Akt1 (Ser473).",
          "judgment": "Yes",
          "reasoning": "The general classes of assays used (in vitro kinase assays and cellular knockdown experiments) are relevant to model the disease mechanism of LRRK2-mediated neurodegeneration through altered kinase activity on Akt1, a key molecule in cell survival pathways.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "In vitro phosphorylation assays used wild-type LRRK2 as a control compared to mutants (R1441C, G2019S, I2020T)... experiments performed with statistical comparisons by one-way ANOVA (n = 3). Knockdown experiments used RNAi control and vector control clones.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type LRRK2) and abnormal (mutant LRRK2) controls were included in the assays. The paper explicitly states replicates (n=3) for statistical analysis in both in vitro and cellular assays.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Mutant LRRK2 exhibits reduced Akt1-phosphorylation activity than wild-type LRRK2... recombinant Akt1 was phosphorylated by recombinant LRRK2 with the three known mutations, i.e., R1441C, G2019S, and I2020T... significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (R1441C, G2019S, I2020T) were used as controls in the assays, comparing their activity to wild-type LRRK2, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Graphical representation of the Akt1 (S473) phosphorylation level... Stars represent statistical comparisons by one-way ANOVA (n = 3); p < 0.005.",
          "judgment": "No",
          "reasoning": "While statistical analyses (ANOVA, p < 0.005) are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood based on functional data for R1441C.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Three known pathogenic variants (R1441C, G2019S, I2020T) were used as controls across the study for comparison with wild-type LRRK2.",
          "judgment": "Less than 11 total controls",
          "reasoning": "Only 3 pathogenic variant controls were used in the study, which is less than the threshold of 11 required for moderate strength evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441C is rated as PS3_supporting due to the clear disease mechanism, relevant assay types, presence of basic and variant controls, but limited by the lack of OddsPath calculation and fewer than 11 control variants used in the study."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the gene responsible for autosomal-dominant PD, PARK8... Accumulated data suggest that the kinase activity of LRRK2 may play a key role in neurodegeneration. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interaction with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegeneration caused by LRRK2 mutations.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neurodegeneration in Parkinson's disease linked to LRRK2 kinase activity, with reduced phosphorylation of Akt1 by mutant LRRK2 as a potential contributor to neuronal loss."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro phosphorylation of Akt1 by LRRK2... recombinant human Akt1 was incubated with recombinant human LRRK2... LRRK2 directly and effectively phosphorylated the heat-denatured Akt1 molecule. Knockdown of LRRK2 diminishes Akt1 phosphorylation in intact cells... transfection of LRRK2-specific RNAi into the cells reduced the level of LRRK2 protein... resulted in a marked reduction of phospho-Akt1 (Ser473).",
          "judgment": "Yes",
          "reasoning": "The general classes of assays used (in vitro kinase assays and cellular knockdown experiments) are relevant to model the disease mechanism of LRRK2-mediated neurodegeneration through altered kinase activity on Akt1, a key molecule in cell survival pathways.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "In vitro phosphorylation assays used wild-type LRRK2 as a control compared to mutants (R1441C, G2019S, I2020T)... experiments performed with statistical comparisons by one-way ANOVA (n = 3). Knockdown experiments used RNAi control and vector control clones.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type LRRK2) and abnormal (mutant LRRK2) controls were included in the assays. The paper explicitly states replicates (n=3) for statistical analysis in both in vitro and cellular assays.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Mutant LRRK2 exhibits reduced Akt1-phosphorylation activity than wild-type LRRK2... recombinant Akt1 was phosphorylated by recombinant LRRK2 with the three known mutations, i.e., R1441C, G2019S, and I2020T... significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (R1441C, G2019S, I2020T) were used as controls in the assays, comparing their activity to wild-type LRRK2, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Graphical representation of the Akt1 (S473) phosphorylation level... Stars represent statistical comparisons by one-way ANOVA (n = 3); p < 0.005.",
          "judgment": "No",
          "reasoning": "While statistical analyses (ANOVA, p < 0.005) are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood based on functional data for G2019S.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Three known pathogenic variants (R1441C, G2019S, I2020T) were used as controls across the study for comparison with wild-type LRRK2.",
          "judgment": "Less than 11 total controls",
          "reasoning": "Only 3 pathogenic variant controls were used in the study, which is less than the threshold of 11 required for moderate strength evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_supporting due to the clear disease mechanism, relevant assay types, presence of basic and variant controls, but limited by the lack of OddsPath calculation and fewer than 11 control variants used in the study."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the gene responsible for autosomal-dominant PD, PARK8... Accumulated data suggest that the kinase activity of LRRK2 may play a key role in neurodegeneration. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interaction with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegeneration caused by LRRK2 mutations.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neurodegeneration in Parkinson's disease linked to LRRK2 kinase activity, with reduced phosphorylation of Akt1 by mutant LRRK2 as a potential contributor to neuronal loss."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro phosphorylation of Akt1 by LRRK2... recombinant human Akt1 was incubated with recombinant human LRRK2... LRRK2 directly and effectively phosphorylated the heat-denatured Akt1 molecule. Knockdown of LRRK2 diminishes Akt1 phosphorylation in intact cells... transfection of LRRK2-specific RNAi into the cells reduced the level of LRRK2 protein... resulted in a marked reduction of phospho-Akt1 (Ser473).",
          "judgment": "Yes",
          "reasoning": "The general classes of assays used (in vitro kinase assays and cellular knockdown experiments) are relevant to model the disease mechanism of LRRK2-mediated neurodegeneration through altered kinase activity on Akt1, a key molecule in cell survival pathways.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "In vitro phosphorylation assays used wild-type LRRK2 as a control compared to mutants (R1441C, G2019S, I2020T)... experiments performed with statistical comparisons by one-way ANOVA (n = 3). Knockdown experiments used RNAi control and vector control clones.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type LRRK2) and abnormal (mutant LRRK2) controls were included in the assays. The paper explicitly states replicates (n=3) for statistical analysis in both in vitro and cellular assays.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Mutant LRRK2 exhibits reduced Akt1-phosphorylation activity than wild-type LRRK2... recombinant Akt1 was phosphorylated by recombinant LRRK2 with the three known mutations, i.e., R1441C, G2019S, and I2020T... significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (R1441C, G2019S, I2020T) were used as controls in the assays, comparing their activity to wild-type LRRK2, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Graphical representation of the Akt1 (S473) phosphorylation level... Stars represent statistical comparisons by one-way ANOVA (n = 3); p < 0.005.",
          "judgment": "No",
          "reasoning": "While statistical analyses (ANOVA, p < 0.005) are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood based on functional data for I2020T.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Three known pathogenic variants (R1441C, G2019S, I2020T) were used as controls across the study for comparison with wild-type LRRK2.",
          "judgment": "Less than 11 total controls",
          "reasoning": "Only 3 pathogenic variant controls were used in the study, which is less than the threshold of 11 required for moderate strength evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I2020T is rated as PS3_supporting due to the clear disease mechanism, relevant assay types, presence of basic and variant controls, but limited by the lack of OddsPath calculation and fewer than 11 control variants used in the study."
    }
  ]
}